News Summary:
On September 3, 2026, Lotus Pharma reported an 84% revenue surge, primarily stemming from its Alvogen US acquisition, despite a 44% decline in net profit due to debt costs and currency losses. Concurrently, PTT, which controls 63% of Lotus via Innobic, is considering delisting Lotus from Taiwan and relisting in Bangkok, signaling potential stake sales for "more profitable investments." S&P projects Alvogen's revenue to drop 17-25% as generic competition erodes its top products, which constitute 60% of the acquired business. Previously, on August 28, Landsbankinn Corporate Finance advised on the sale of the entire share capital of Alvogen ehf., an Icelandic pharmaceutical wholesaler that commenced operations in 2014, to Orbital ehf. Earlier, on August 13, Lotus Pharmaceutical had announced record revenue for the first half of 2026, largely driven by the Alvogen acquisition and B2B sales. In late July, Maryland Attorney General Anthony Brown announced settlements totaling over $13 million with seven opioid drug manufacturers, including Alvogen, resolving allegations that their manufacturing, marketing, and sales practices contributed to the widespread diversion of prescription opioids.
Subscribe for full access to Alvogen's profile
Subscribe for full access to Alvogen's products in full detail 
